Commercial deals were signed for the Padcev-Keytruda combo regimen, challenging Opdivo market share, with NHS adoption pending FDA approval.
1 report, 1 independent
Updated Aug 22
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Commercial deals were signed for the Padcev-Keytruda combo regimen, challenging Opdivo market share, with NHS adoption pending FDA approval.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
National Health Service
publicly funded healthcare system of England
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
-
MSD
company in Rome, Italy
Related events
- FDA approval supports commercial partner contracts for Vericel.
- OS Therapies, Inc. is seeking interim and final review data submissions from regulatory bodies while attending major global investment conferences.
- Alnylam and BridgeBio received label expansion approvals in the EU, while Pfizer's therapies compete in the ATTR-CM market.
- OPKO Health announced asset sales, advanced an EBV vaccine Phase 1 trial, and saw FDA approval for prostate cancer screening.
- FDA approval clears the path for drug market entry, driving future regulatory focus for major pharmaceutical companies.
Coverage
Newest first; wire copies grouped- Pharmaceutical TechnologyPadcev-Keytruda combo approved for NHS use in mUC The UK’s National Institute for Health and Care Excellence (NICE) has recommended a new combination regimen in metastatic urothelial carcinoma (mUC)